NCT00152503

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

An Open Label, Exploratory, Dose-escalation, Multicenter Study Examining the Safety, Tolerability and Efficacy of Ucb 44212 (Seletracetam) Used at Doses of 10, 20, 40, and 80 mg b.i.d. (Total Daily Doses of 20 - 160 mg) Administration (Oral Capsules) in Adult Subjects (18 - 65 Years) With Refractory Epilepsy Suffering From Partial Onset Seizures Who Are Currently Receiving Levetiracetam (LEV) But Still Experiencing Seizures

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: UCB Pharma SA · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This trial will evaluate the efficacy and safety of UCB44212 as add-on therapy in subjects with focal epilepsy.

Conditions

• Epilepsy, Partial

Interventions

Type	Name	Description
DRUG	Seletracetam (UCB44212)	* Pharmaceutical form: oral capsules * Concentration: 2, 10 and 50 mg * Route of administration: oral administration

Timeline

• Start date: 2005-08-31
• Primary completion: 2006-05-12
• Completion: 2006-05-12
• First posted: 2005-09-09
• Last updated: 2023-09-07
• Results posted: 2023-09-07

Locations

17 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study